Skip to content

Study · Animal study (in vivo) · rat · 2001

3 results

Paraventricular hypothalamic alpha-melanocyte-stimulating hormone and MTII reduce feeding without causing aversive effects.

Wirth MM, Olszewski PK, Yu C, Levine AS, Giraudo SQ

Peptides1 Jan 2001Cited by 92 (Europe PMC)

PMID11179607 (opens in a new tab)DOI10.1016/s0196-9781(00)00367-3 (opens in a new tab)PepBankPUB-11179607
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, administration of MTII into the paraventricular nucleus decreased nocturnal food intake.

    In plain wordsIn rats, MTII given into a brain area called the PVN reduced night-time food intake.

    Peptide
    Melanotan II
    Outcome
    DecreaseNocturnal food intake
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intra-PVNAs given in this study (rat).

    Source sentences

    Summary
    The current studies demonstrate that PVN administration of alpha-MSH or MTII decreases nocturnal and NPY-stimulated food intake without causing aversive effects.
    1 context sentence
    Summary · context
    MTII, a specific synthetic MC3-R/MC4-R agonist, has similar effects on feeding in rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, co-administration of 1 pmol MTII with NPY into the paraventricular nucleus significantly decreased NPY-induced feeding.

    In plain wordsIn rats, a very small dose of MTII given with NPY into the PVN reduced the feeding that NPY causes.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-induced feeding
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 pmol · intra-PVNAs given in this study (rat).

    Measurements

    dose
    1 pmol
    MTII with NPY in PVN

    Source sentences

    Summary
    Co-administration with NPY of 600 pmol alpha-MSH or 1 pmol MTII into the PVN caused a significant decrease in NPY-induced feeding.
    1 context sentence
    Summary · context
    MTII, a specific synthetic MC3-R/MC4-R agonist, has similar effects on feeding in rats.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, PVN administration of MTII at doses that suppressed feeding did not cause conditioned taste aversion.

    In plain wordsIn rats, MTII given into the PVN at doses that cut feeding did not cause a learned dislike of taste.

    Peptide
    Melanotan II
    Outcome
    No significant changeConditioned taste aversion after PVN administration
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · intra-PVNAs given in this study (rat).

    Source sentences

    Summary
    PVN administration of MTII or alpha-MSH at doses effective to suppress feeding did not cause conditioned taste aversion (CTA).
    1 context sentence
    Summary · context
    MTII, a specific synthetic MC3-R/MC4-R agonist, has similar effects on feeding in rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.